iRhythm Q1 revenue $131.9M (+18.4% YoY); net loss widens to $45.7M; raises FY revenue guidance to $578-588M

iRhythm Holdings, Inc.

2024-Q1 EPS reported -$1.47 revenue$131,929,000

Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).
Net loss $45.7M ($1.47/share) vs $39.1M ($1.29) YoY; adjusted loss $38.1M ($1.23) vs $33.4M ($1.10).
FY2024 revenue guidance raised to $578-588M (17-19% growth); gross margin 68-69%, adj. EBITDA margin 3-4%.
Over 500K registrations in Q1; announced Epic Aura collaboration for EMR integration; heart failure prediction data presented at ACC.
Unrestricted cash, equivalents, and marketable securities $569.1M as of March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

iRhythm Holdings, Inc. reported three months ended March 31, 2024 results: revenue $131.9 million, net income $45.7 million, or a diluted loss of $1.47 per share, EPS $1.47 per share. Guidance raised.

Period: three months ended March 31, 2024
Revenue: $131.9 million
Net income: $45.7 million, or a diluted loss of $1.47 per share
EPS: $1.47 per share
Guidance: raised
Result: reported results

Exact text from the filing

that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights • Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023 • Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023 • Unrestricted cash, cash equivalents and

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

iRhythm Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001388658-24-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.